CN1456351A - Self-emulsifying agglomerant of oral polypeptide medicine - Google Patents
Self-emulsifying agglomerant of oral polypeptide medicine Download PDFInfo
- Publication number
- CN1456351A CN1456351A CN 03128843 CN03128843A CN1456351A CN 1456351 A CN1456351 A CN 1456351A CN 03128843 CN03128843 CN 03128843 CN 03128843 A CN03128843 A CN 03128843A CN 1456351 A CN1456351 A CN 1456351A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- medicine according
- oral
- medicine
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
An oral-applied self-emulsifying polypeptide medicine is prepared from polypeptide, gel adhesive, surfactant, co-surfactant, oil enzyme inhibitor, and diluent. Its preparing process is also disclosed. It features that after it comes in intestinal tract, it is emulsified by itself to become nano-class microemulsion, which can penetrate through intestinal mucosa and epithelial barrier into lymph and blood, and be attached on intestinal inner surface to promote its absorption.
Description
Technical field
The present invention relates to a kind of oral polypeptide drug preparation and preparation method thereof.
Background technology
Along with biotechnology and engineered development, increasing polypeptide and protein medicaments are used for clinical treatment, and the most biologically active of polypeptide drug is all unstable to multiple factors such as heat and enzymes, so the normal drug administration by injection that adopts.But secular drug administration by injection brings great misery to the patient, and needs special injection technique, and the patient is difficult to autonomous administration, the finished product height, and medical expense is big.Therefore, both at home and abroad the pharmacy worker is devoted to the research of the non-injecting pathway of polypeptide drug always, as nasal cavity, rectum, oral, lung, eye, Transdermal absorption etc.In above-mentioned route of administration, oral administration is because of it is easy, directly perceived, patient's compliance is good, acceptable degree is high, and particularly noticeable.But if such medicine is directly oral without special embedding technical finesse, owing to: 1. the effect of gastric juice sour environment and digestive enzyme makes its inactivation; 2. usually molecular weight is bigger, and intermolecular stronger polymerization trend is arranged, so be difficult to by diffusion through intestinal wall; 3. the first-pass effect of liver.Have only 0.1～2% as the direct oral bioavailability of INS, do not have clinical use value.Oral administration research for polypeptide drug such as INS is a lot, liposome, Emulsion, enteric coated preparation etc. are arranged, but bioavailability does not surpass 5% yet; Some novel drug-supplying systems have been used for the oral administration of INS in recent years, and as nanoparticle (capsule), microemulsion, colon-specific drug delivery system etc., but the result is still undesirable.
Summary of the invention
The technical issues that need to address of the present invention are to disclose a kind of oral polypeptide drug self emulsifying agglomerate and preparation method thereof, to overcome the above-mentioned defective that prior art exists.
The invention still further relates to a kind of preparation that contains described oral polypeptide drug.
Technical conceive of the present invention is such:
The inventor is with the aqueous solution and the surfactant of polypeptide drug, cosurfactant, oil, the water-soluble biological adhesive agent, mixings such as diluent, through lyophilization or spray drying, promptly get and contain medicine, has bioadhesive, but and the pressed powder of self emulsifying, after entering intestinal, self emulsifying becomes the nanoscale microemulsion, fat-soluble increase, be easy to see through intestinal mucosa, contain and see through the epithelium barrier behind the M cell traffic in the aggregated lymphatic follicles that the lipid breast grain of medicine can be in mucous membrane of small intestine (Peyer ' s paches) and enter lymph and blood circulation, contain bioadhesive material in the preparation, can imbibition in small intestinal, adhere to intestinal wall, the soak time of prolong drug, thereby the bioavailability of raising polypeptide drug.
The component and the weight percent content of oral polypeptide drug of the present invention comprise:
Polypeptide 0.1～50%
Gel adhesive agent 5～75%
Surfactant 10～80%
Grease 5～50%
Diluent 0～79.9%
Said polypeptide comprises a kind of in insulin (pig, cattle, insulin human), parathyroid hormone and each segment, vassopressin and derivant thereof, Desmopressin, LHRH, nafarelin, interferon, the interleukin.
Said gel adhesive agent be for absorbing water and form the macromolecular material of gel, and the gelatin substance of natural extract preferably is as alginate, arabic gum, Lac, chitosan, tragakanta, pectin, agar; The high score material of synthetic: hydroxypropyl emthylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose; Or amylodextrin class material: as starch and derivant thereof, α, one or more in beta, gamma-cyclodextrin and the derivant thereof etc.
Said surfactant comprises Polysorbate, poloxamer, Myrij (Mjri), Brij (Brij), lecithin, soybean phospholipid, sodium lauryl sulphate, glyceryl monostearate, one or more in sucrose ester, the polyoxyethylene castor oil condensation substance etc.
Cosurfactant comprises the gelatin substance of natural extract, as alginate, arabic gum, Lac, chitosan, tragakanta, pectin, agar; The high score material of synthetic: hydroxypropyl emthylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose; In ethanol, the propylene glycol etc. one or more.
Said grease comprises vegetable oil esters, as soybean oil, and vegetable oil or Semen arachidis hypogaeae wet goods, C
8～C
16Fatty glyceride, decanoyl/octanoyl glycerides preferably.
Said enzyme inhibitor comprises one or more in bacitracin, chitosan, NaGC, Guang albumen, leupeptin or the bestatin etc.
Said diluent comprises one or more in starch and derivant, lactose, mannitol, sorbitol, chitosan, cellulose and derivant thereof, cyclodextrin and the derivant thereof etc.
The invention still further relates to a kind of preparation that contains described oral polypeptide drug, said preparation comprises said oral polypeptide drug and medicine and pharmacology acceptable carrier, said carrier comprises adhesive agent and/or disintegrating agent and/or diluent etc., thereby can adopt method well known in the art to be prepared into tablet or capsule described oral polypeptide drug.
Said adhesive agent comprises cellulose derivative, alginate, gelatin, chitosan etc.;
Said disintegrating agent comprises cross-linked carboxymethyl cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, the fine cellulose of crystallite, starch and derivant thereof etc.;
It is 0.1%～99.5% oral polypeptide drug self emulsifying agglomerate that the preparation that contains oral polypeptide drug of the present invention preferably contains weight ratio.
Oral polypeptide drug self emulsifying agglomerate and adhesive agent, disintegrating agent, diluent compacting are in flakes, and be outer enteric coated, or directly be packed in the enteric coated capsule, to avoid peptic digestion liquid and pepsic destruction.
The preparation method of oral polypeptide drug self emulsifying agglomerate of the present invention comprises the steps:
(1) polypeptide and gel adhesive agent, the diluent of being addressed is dissolved in an amount of aqueous solution, swelling, standby; Said aqueous solution comprises can make the dissolved acid of polypeptide (example hydrochloric acid etc.) solution, alkali (as sodium hydroxide etc.) solution, buffer salt solution etc.
(2) surfactant, cosurfactant, oil are mixed in proportion after, contain medicine hydrogel mixing completely with swelling, through lyophilizing in 10～30 hours or directly carry out spray drying, promptly get pastille self emulsifying powder, it can be dispersed into microemulsion (particle diameter is 10～500nm, and great majority are between 10～300nm) in aqueous medium.
(3) with made self emulsifying powder in (2), press required dosage,,, directly be filled into enteric coated capsule with diluent, disintegrating agent, adhesive agent, binding agent system granule with conventional preparation method, or be pressed into behind the tablet outer enteric coated, promptly.
The amount of application of said medicine of the present invention can be determined according to the order of severity of patient's age, body weight, disease and type etc.
Characteristics of the present invention:
Polypeptide drug is made self-emulsifying drug delivery systems carry out administration, after preparation entered intestinal, self emulsifying became the nanoscale microemulsion, and fat-soluble increase is easy to see through intestinal mucosa; The lipid breast grain that contains medicine can see through the epithelium barrier in small intestinal and behind the M cell traffic in Peyer district and enter lymph and blood circulation;
Contain bioadhesive material in the preparation, can imbibition in small intestinal, adhere to intestinal wall, the soak time of prolong drug;
Add a small amount of enzyme inhibitor in the preparation, only adhere to the position inhibitory enzyme activity, do not destroy the normal microecosystem of intestinal at preparation;
The preferred chitosan that adds not only has stronger adhesion property, and has certain enzyme inhibition as bioadhesive polymer in the preparation, can effectively promote the absorption of polypeptide drug.
Description of drawings
Fig. 1 is that the rat blood sugar behind the gastric infusion changes.
Fig. 2 is that the rat blood sugar behind the duodenal administration changes.
The specific embodiment
With insulin (Insulin, INS) 1g, Polysorbate 1g, polyoxyethylene hydrogenated Oleum Ricini 2.5g, suffering/caprin 2g, ethanol 0.5g, chitosan 0.5g, water 15ml, the pH regulator agent is an amount of, behind the dissolving mixing, through lyophilization in 20 hours, promptly get oral self emulsifying polypeptide drug agglomerate of the present invention.
With parathyroid hormone 0.1g, Polysorbate 1g, polyoxyethylene hydrogenated Oleum Ricini 2.5g, Oleum Arachidis hypogaeae semen 2g, ethanol 0.5g, chitosan 2.5g, water 30ml, behind the dissolving mixing, through lyophilization in 30 hours, promptly get oral self emulsifying polypeptide drug agglomerate of the present invention.
With INS 2g, chitosan 0.5g, add 0.1N hydrochloric acid 10ml dissolving after, add polyoxyethylene hydrogenated Oleum Ricini 2.5g, Oleum Arachidis hypogaeae semen 1g, water 50ml, behind the dissolving mixing, directly spray drying promptly gets oral self emulsifying polypeptide drug agglomerate of the present invention.
Embodiment 4
With INS 1g, hydroxy propyl cellulose 0.5g, mannitol 5, add 0.1N hydrochloric acid 30ml dissolving after, addition polymerization Pyrusussuriensis ester 2g, suffering/caprin 3g behind the mixing, through lyophilization in 20-30 hour, promptly get oral self emulsifying polypeptide drug agglomerate of the present invention.
Oral polypeptide drug agglomerate 30 grams of embodiment 1, pregelatinized Starch 50g, chitosan 20g, low-substituted hydroxypropyl cellulose 1g, Pulvis Talci is an amount of, behind the mixing, adopt method well known in the art, be prepared into tablet, again outsourcing enteric acrylic resin, wherein, oral polypeptide drug content is every 100IU.
Embodiment 6 animal absorption tests:
Laboratory animal: SD rat
Administering mode:
A.INS solution gastric infusion, 40IU/kg;
B. pastille agglomerate microemulsion administration, 40IU/kg;
C.INS solution duodenal administration, 40IU/kg;
D. pastille agglomerate microemulsion duodenal administration, 40IU/kg;
Test method: get normal SD rats, totally 20, be divided into 4 groups at random, 5 every group, each group is irritated stomach and is given IND solution 40IU/kg, and second group gives pastille agglomerate microemulsion with method; Per three groups of rats by intraperitoneal injection pentobarbital sodiums (50mg/kg) anesthesia is lain on the back and is fixed on the plank, along the hunter's line median incision, isolates duodenum, with syringe the INS aqueous solution is injected duodenum; The 4th group of rat gives pastille agglomerate microemulsion with the 3rd group.Get blood 60ul at regular intervals, use determination of glucose oxidase blood glucose, measurement result is seen Fig. 1 and 2:
Result of the test shows that the bioadhesion self-emulsified drug delivery system can increase the absorption of the oral back of polypeptide drug at intestinal effectively.As direct oral administration, then will be because of pepsic destruction makes drug failure, so should make enteric coated preparation.Adding enzyme inhibitor in preparation can make the absorption of medicine increase.
Claims (11)
1. oral polypeptide drug self emulsifying agglomerate is characterized in that component and weight percent content comprise:
Polypeptide 0.1～50%
Gel adhesive agent 5～75%
Surfactant 10～80%
Cosurfactant 0～20%
Grease 5～50%
Enzyme inhibitor 0～5%
Diluent 0～79.9%.
2. medicine according to claim 1, it is characterized in that said polypeptide comprises a kind of in insulin (pig, cattle, insulin human), parathyroid hormone and each segment, vassopressin and derivant thereof, Desmopressin, LHRH, nafarelin, interferon, the interleukin.
3. medicine according to claim 1 is characterized in that, said gel adhesive agent is for absorbing water and form the macromolecular material of gel.
4. medicine according to claim 3, it is characterized in that the gel adhesive agent is alginate, arabic gum, Lac, chitosan, tragakanta, pectin, agar, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose or amylodextrin class material.
5. medicine according to claim 1, it is characterized in that, said surfactant comprises Polysorbate, poloxamer, Myrij (Mjri), Brij (Brij), lecithin, soybean phospholipid, sodium lauryl sulphate, glyceryl monostearate, one or more in sucrose ester, the polyoxyethylene castor oil condensation substance etc.
6. medicine according to claim 1, it is characterized in that cosurfactant comprises one or more in alginate, arabic gum, Lac, chitosan, tragakanta, pectin, agar, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, ethanol or the propylene glycol.
7. medicine according to claim 1 is characterized in that said grease comprises vegetable oil esters, C
8～C
16Fatty glyceride.
8. medicine according to claim 1 is characterized in that, said enzyme inhibitor comprises one or more in bacitracin, chitosan, NaGC, Guang albumen, leupeptin or the bestatin.
9. medicine according to claim 1 is characterized in that, said diluent comprises one or more in starch and derivant, lactose, mannitol, sorbitol, chitosan, cellulose and derivant thereof, cyclodextrin and the derivant thereof.
10. a preparation that contains each described oral polypeptide drug of claim 1～9 is characterized in that, said preparation comprises said oral polypeptide drug self emulsifying agglomerate and medicine and pharmacology acceptable carrier.
11. the preparation method according to each described oral polypeptide drug self emulsifying agglomerate of claim 1～9 is characterized in that, comprises the steps:
(1) polypeptide and gel adhesive agent, the diluent of being addressed is dissolved in an amount of aqueous solution, swelling, standby;
(2) surfactant, cosurfactant, oil are mixed in proportion after, contain medicine hydrogel mixing completely with swelling, lyophilizing or directly carry out spray drying, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03128843XA CN100453115C (en) | 2003-05-26 | 2003-05-26 | Self-emulsifying agglomerant of oral polypeptide medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03128843XA CN100453115C (en) | 2003-05-26 | 2003-05-26 | Self-emulsifying agglomerant of oral polypeptide medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456351A true CN1456351A (en) | 2003-11-19 |
| CN100453115C CN100453115C (en) | 2009-01-21 |
Family
ID=29411697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03128843XA Expired - Fee Related CN100453115C (en) | 2003-05-26 | 2003-05-26 | Self-emulsifying agglomerant of oral polypeptide medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100453115C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400097C (en) * | 2005-08-22 | 2008-07-09 | 上海医药工业研究院 | Insulin liquid formulations for nose administration |
| WO2009094846A1 (en) * | 2007-12-28 | 2009-08-06 | Shanghai Institute Of Pharmaceutical Industry | Insulin nasal powder inhalation |
| WO2012113117A1 (en) * | 2011-02-24 | 2012-08-30 | 美迪思生物科技(北京)有限公司 | Oral preparation comprising protein or polypeptide, preparation method thereof, and use thereof |
| CN102907583A (en) * | 2012-10-27 | 2013-02-06 | 北京大北农科技集团股份有限公司 | Porcine beta defensin-2 spray-dried powder, feed additive, premix and batch |
| CN106334185A (en) * | 2016-08-25 | 2017-01-18 | 广东省人民医院 | Polypeptide drug-containing self-nano-emulsion oral preparation and preparation method thereof |
| CN108578356A (en) * | 2018-03-09 | 2018-09-28 | 昆药集团股份有限公司 | A kind of Artemether oral microemulsion in-situ gel and preparation method thereof |
| CN109588551A (en) * | 2018-11-21 | 2019-04-09 | 南宁市黄陈生猪养殖场 | A kind of feed addictive and preparation method thereof for treating metabolic disease |
| WO2023089240A1 (en) | 2021-11-19 | 2023-05-25 | Nanoform Finland Oyj | A composition comprising nanosized active pharmaceutical ingredient |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11504028A (en) * | 1995-04-24 | 1999-04-06 | イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム | Self-emulsifying compounds that create oil / water emulsions |
| IL138616A0 (en) * | 2000-09-21 | 2001-10-31 | J P M E D Ltd | Oil in glycerin emulsion |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
-
2003
- 2003-05-26 CN CNB03128843XA patent/CN100453115C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400097C (en) * | 2005-08-22 | 2008-07-09 | 上海医药工业研究院 | Insulin liquid formulations for nose administration |
| WO2009094846A1 (en) * | 2007-12-28 | 2009-08-06 | Shanghai Institute Of Pharmaceutical Industry | Insulin nasal powder inhalation |
| WO2012113117A1 (en) * | 2011-02-24 | 2012-08-30 | 美迪思生物科技(北京)有限公司 | Oral preparation comprising protein or polypeptide, preparation method thereof, and use thereof |
| CN102907583A (en) * | 2012-10-27 | 2013-02-06 | 北京大北农科技集团股份有限公司 | Porcine beta defensin-2 spray-dried powder, feed additive, premix and batch |
| CN102907583B (en) * | 2012-10-27 | 2018-06-15 | 北京大北农科技集团股份有限公司 | 2 spray powder of pig beta-defensin, feed addictive, premix and batch |
| CN106334185A (en) * | 2016-08-25 | 2017-01-18 | 广东省人民医院 | Polypeptide drug-containing self-nano-emulsion oral preparation and preparation method thereof |
| CN106334185B (en) * | 2016-08-25 | 2020-01-10 | 广东省人民医院 | Oral preparation containing polypeptide drug self-nanoemulsion and preparation method thereof |
| CN108578356A (en) * | 2018-03-09 | 2018-09-28 | 昆药集团股份有限公司 | A kind of Artemether oral microemulsion in-situ gel and preparation method thereof |
| CN108578356B (en) * | 2018-03-09 | 2021-04-27 | 昆药集团股份有限公司 | Artemether oral microemulsion in-situ gel and preparation method thereof |
| CN109588551A (en) * | 2018-11-21 | 2019-04-09 | 南宁市黄陈生猪养殖场 | A kind of feed addictive and preparation method thereof for treating metabolic disease |
| WO2023089240A1 (en) | 2021-11-19 | 2023-05-25 | Nanoform Finland Oyj | A composition comprising nanosized active pharmaceutical ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100453115C (en) | 2009-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5175017B2 (en) | Particulate carrier for improving oral absorption of active ingredients | |
| CN102149368B (en) | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin | |
| CA2045472C (en) | Drug delivery compositions | |
| FI97444C (en) | A method of making a drug delivery system | |
| US5554388A (en) | Systemic drug delivery compositions comprising a polycationi substance | |
| US20110189299A1 (en) | Pharmaceutical composition containing surface-coated microparticles | |
| US20020054914A1 (en) | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein | |
| US20100278922A1 (en) | Methods and compositions for oral administration of insulin | |
| US20030078194A1 (en) | Pro-micelle pharmaceutical compositions | |
| CN102014880A (en) | Therapeutic calcium phosphate particles and methods of making and using same | |
| US20060127489A1 (en) | Targeted delivery | |
| CN1915215A (en) | Oral cavity disintegration preparation | |
| CN1456351A (en) | Self-emulsifying agglomerant of oral polypeptide medicine | |
| CN1438881A (en) | The Controlled release preparation of insulin and its method | |
| CN102125520A (en) | Emulsion containing hydrophilic biological macromolecule, preparation method and application thereof | |
| CN103037884A (en) | Pharmaceutical or neutraceutical formulation | |
| Mesiha et al. | Increased oral absorption enhancement of insulin by medium viscosity hydroxypropyl cellulose | |
| Ma et al. | Preliminary study of oral polylactide microcapsulated insulin in vitro and in vivo | |
| CN106581646A (en) | Oral insulin composition | |
| CN100400097C (en) | Insulin liquid formulations for nose administration | |
| Elçioğlu et al. | Nanoparticle insulin drug delivery—applications and new aspects | |
| CN1310647C (en) | Anti-cold medicine soft capsule and its preparing method | |
| CN113893333A (en) | Insulin sustained-release oral patch and preparation method and application thereof | |
| CN1075945C (en) | High-polymer encapsulated insulin microsome and its preparation method and use | |
| WO2004084947A1 (en) | Pharmaceutical composition comprising fungal cell or fragment thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090121 Termination date: 20150526 |
|
| EXPY | Termination of patent right or utility model |